Literature DB >> 7268629

Synergism between acid and gastric contractile activity in the genesis of ulceration and hemorrhage in the phenylbutazone-treated rat.

W A Mersereau, E J Hinchey.   

Abstract

The nonsteroid anti-inflammatory drugs including phenylbutazone produce significant gastric ulceration and hemorrhage even when administered by an extragastric route. To investigate the mechanism involved, cervical sectioned rats received an intraileal injection of phenylbutazone as the sodium salt in methylcellulose. Gastric contractile activity as recorded with a miniature gastric balloon, and the stomach was perfused with either acid at pH 1 or buffer at pH 7. Rats receiving phenylbutazone developed a pattern of abnormally strong contractile activity that began 60 to 90 minutes after drug administration. The contracting stomachs of rats perfused with acid developed significantly more ulceration and bled more severely than buffer-perfused rats. Vagotomy or atropine prevented the gastric contractile response to phenylbutazone, and such rats failed to develop significant ulceration in spite of the fact that their stomachs were perfused with acid. Cervical sectioned rats treated with methylcellulose alone failed to develop the abnormal contractile pattern and showed no significant gastric injury or hemorrhage. It is concluded that the focal hemorrhagic lesions induced by the extragastric administration of phenylbutazone in the rat are the result of mucosal compression at specific sites secondary to the passage of extremely strong peristaltic waves. They are vagally mediated and although the presence of acid does not appear essential for their initiation, it plays a synergistic role in their development and hemorrhage.U

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7268629

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

1.  Old belief that gastrointestinal injury by the NSAID is due to direct contact.

Authors:  W A Mesereau
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

2.  Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin.

Authors:  A Anthony; R E Pounder; A P Dhillon; A J Wakefield
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

3.  Relationship between gastric mucosal hemodynamics and gastric motility.

Authors:  T Yamaguchi
Journal:  Gastroenterol Jpn       Date:  1990-06

4.  Relative roles of acid and mucosal compression in ulcerogenesis in indomethacin-insulin-treated rat.

Authors:  W A Mersereau; D C Lehotay; E J Hinchey
Journal:  Dig Dis Sci       Date:  1988-11       Impact factor: 3.199

5.  Protection against necrotizing agents-induced gastric lesions in rats. Unrelated to inhibition of gastric motility.

Authors:  C A Gutiérrez-Cabano
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

6.  Effects of parenteral diclofenac sodium on upper gastrointestinal motility after food in man.

Authors:  G Bassotti; G Bucaneve; C Betti; L Patoia; E Baratta; V Maresca; M A Pelli; A Morelli; A Del Favero
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Role of local motility changes in the pathogenesis of duodenal ulcers induced by cysteamine in rats.

Authors:  K Takeuchi; H Nishiwaki; S Okabe
Journal:  Dig Dis Sci       Date:  1987-03       Impact factor: 3.199

8.  Relationship between the gastric myoelectric and mechanical activity in the genesis of ulcers in indomethacin-insulin-treated rats.

Authors:  W A Mersereau; E J Hinchey
Journal:  Dig Dis Sci       Date:  1988-02       Impact factor: 3.199

9.  Effects of acetylsalicylic acid on electromechanical activity of in vivo rabbit ileum.

Authors:  K L Koch; A Dwyer
Journal:  Dig Dis Sci       Date:  1988-08       Impact factor: 3.199

10.  Enhancement by intracerebroventricular thyrotropin-releasing hormone of indomethacin-induced gastric lesions in the rat.

Authors:  M Maeda-Hagiwara; H Watanabe; K Watanabe
Journal:  Br J Pharmacol       Date:  1983-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.